Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 192,248 | 100,304 | 66,398 | 33,498 | 36,396 |
| Marketable Securities | 163,770 | 39,736 | 23,723 | 28,692 | 37,940 |
| Receivables | 102,922 | 65,586 | 41,527 | 25,908 | 17,270 |
| Inventories | 25,659 | 16,304 | 16,801 | 12,587 | 13,441 |
| TOTAL | $493,487 | $228,451 | $151,404 | $105,946 | $108,726 |
| Non-Current Assets | |||||
| PPE Net | 4,095 | 5,124 | 4,344 | 3,874 | 2,448 |
| Investments And Advances | 418,798 | 133,638 | 75,410 | 55,009 | 19,816 |
| Intangibles | 31,368 | 36,019 | 36,350 | 976 | 225 |
| Other Non-Current Assets | 30,063 | 21,232 | 42,060 | 22,821 | 5,569 |
| TOTAL | $484,324 | $196,013 | $158,164 | $82,680 | $28,058 |
| Total Assets | $977,811 | $424,464 | $309,568 | $188,626 | $136,784 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,195 | 6,844 | 8,055 | 4,314 | 1,863 |
| Accrued Expenses | 155,975 | 111,586 | 69,377 | 51,947 | 26,117 |
| Other current liabilities | 2,183 | 4,283 | 3,101 | 497 | 0 |
| TOTAL | $161,353 | $123,000 | $80,742 | $56,934 | $28,123 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | 287 | 209 | 176 | 143 |
| aiOther Non-Current Liabilities | 363,435 | 32,835 | 35,570 | 42,295 | 66,688 |
| TOTAL | $363,435 | $33,984 | $37,071 | $43,685 | $67,962 |
| Total Liabilities | $524,788 | $156,984 | $117,813 | $100,619 | $96,085 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 52,320 | 51,537 | 50,163 | 49,400 | 44,089 |
| Common Shares | 52 | 51 | 50 | 49 | 43 |
| Retained earnings | 86,492 | -26,823 | -84,288 | -175,509 | -189,453 |
| Other shareholders' equity | -3,158 | -747 | -134 | -488 | -154 |
| TOTAL | $453,023 | $267,480 | $191,755 | $88,007 | $40,699 |
| Total Liabilities And Equity | $977,811 | $424,464 | $309,568 | $188,626 | $136,784 |